Trial Profile
A First in Man Evaluation of the Safety and Efficacy of an Allogeneic Targeted Microbiome Transplant in Adults With Moderate-to-Severe Atopic Dermatitis (ADRN-08)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs MSB-0221 (Primary)
- Indications Atopic dermatitis; Staphylococcal infections
- Focus Adverse reactions; First in man
- Acronyms ADRN-08
- 22 Feb 2021 According to MatriSys Bioscience media release, the data from this trial were published in Nature Medicine journal.
- 22 Feb 2021 Results published in the MatriSys Bioscience media release.
- 19 Jun 2019 Status changed from recruiting to completed.